Phathom Pharmaceuticals Stock Today
| PHAT Stock | USD 17.66 0.41 2.38% |
PerformanceSolid
| Odds Of DistressHigh
|
Phathom Pharmaceuticals is selling for under 17.66 as of the 24th of December 2025; that is 2.38 percent increase since the beginning of the trading day. The stock's last reported lowest price was 17.37. Phathom Pharmaceuticals has more than 62 % chance of experiencing financial distress in the next few years of operation. However, it had a very solid returns during the last 90 days. The performance scores are derived for the period starting the 25th of September 2025 and ending today, the 24th of December 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of October 2019 | Category Healthcare | Classification Health Care |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. The company has 71.14 M outstanding shares of which 12.74 M shares are at this time shorted by private and institutional investors with about 13.26 trading days to cover. More on Phathom Pharmaceuticals
Moving against Phathom Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Phathom Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Terrie Curran | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsPhathom Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Phathom Pharmaceuticals' financial leverage. It provides some insight into what part of Phathom Pharmaceuticals' total assets is financed by creditors.
| |||||
Phathom Pharmaceuticals (PHAT) is traded on NASDAQ Exchange in USA and employs 427 people. Phathom Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.23 B. Phathom Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 71.14 M outstanding shares of which 12.74 M shares are at this time shorted by private and institutional investors with about 13.26 trading days to cover.
Phathom Pharmaceuticals currently holds about 207.39 M in cash with (266.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.39.
Check Phathom Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationPhathom Pharmaceuticals owns a total of 71.14 Million outstanding shares. The majority of Phathom Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Phathom Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Phathom Pharmaceuticals. Please pay attention to any change in the institutional holdings of Phathom Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Phathom Ownership Details
Phathom Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-06-30 | 1.1 M | |
| Avidity Partners Management Lp | 2025-06-30 | 1.1 M | |
| Gw&k Investment Management, Llc | 2025-06-30 | 1 M | |
| Propel Bio Management Llc | 2025-06-30 | 922.9 K | |
| State Street Corp | 2025-06-30 | 849.4 K | |
| Catalio Capital Management, Lp | 2025-06-30 | 672.3 K | |
| Moore Capital Management, Lp | 2025-06-30 | 600 K | |
| Simplify Asset Management Inc. | 2025-06-30 | 521.9 K | |
| Citigroup Inc | 2025-06-30 | 517.2 K | |
| Medicxi Ventures Management (jersey) Ltd | 2025-06-30 | 7.5 M | |
| Amvescap Plc. | 2025-06-30 | 4.1 M |
Phathom Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Phathom Pharmaceuticals market risk premium is the additional return an investor will receive from holding Phathom Pharmaceuticals long position in a well-diversified portfolio.
| Mean Deviation | 2.5 | |||
| Semi Deviation | 2.43 | |||
| Standard Deviation | 3.17 | |||
| Variance | 10.04 |
Phathom Stock Against Markets
Phathom Pharmaceuticals Corporate Management
| Robert Breedlove | VP Officer | Profile | |
| Joseph JD | Chief Officer | Profile | |
| Mark Devlin | Senior Access | Profile | |
| Susan Kim | Senior Marketing | Profile | |
| Tom Harris | Chief Officer | Profile | |
| Martin Gilligan | Chief Officer | Profile | |
| JD Esq | General Secretary | Profile |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.